Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk Stock Hits Record High as Wegovy Maker Sees Up To 26% Sales Growth This Year
10:36am, Wednesday, 31'st Jan 2024
The American depositary receipts (ADRs) of Novo Nordisk (NVO), the market leader in weight-loss drugs, rose sharply in early trading Wednesday, hitting an all-time high, after the Danish company said
Novo Nordisk (NVO) Q4 Earnings Top, GLP-1 Drugs Boost Sales
10:26am, Wednesday, 31'st Jan 2024
Novo Nordisk (NVO) reports better-than-expected fourth-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.
Novo Nordisk CEO on Q4 results, soaring demand for Wegovy and Ozempic
08:08am, Wednesday, 31'st Jan 2024
Novo Nordisk president and CEO Lars Fruergaard Jørgensen joins 'Squawk Box' to discuss the company's quarterly earnings results, which reported better-than-expected 2023 earnings, surging demand for
Norway's giant wealth fund touts possibility of Novo Nordisk, Eli Lilly joining the trillion-dollar club
06:46am, Wednesday, 31'st Jan 2024
Norway's giant wealth fund says Novo Nordisk and Eli Lilly could be on course to become the first health care companies to join the trillion-dollar club.
Best Growth Stocks to Buy for January 31st
05:25am, Wednesday, 31'st Jan 2024
TX, POWL and NVO made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 31, 2024.
Weight-Loss Drug Boom Sends Novo Nordisk Profits Soaring. Why the Success Brings Challenges.
05:20am, Wednesday, 31'st Jan 2024
It's on to a real winner with its Wegovy treatment. The company's market capitalization climbed past $500 billion early Wednesday.
Catalent's Indiana plant is filling Wegovy pens to Novo Nordisk for U.S. - ceo
05:04am, Wednesday, 31'st Jan 2024
Novo Nordisk's CEO Lars Fruergaard Jorgensen confirmed on Wednesday that Catalent's Indiana plant in the United States has started filling injection pens for its obesity drug Wegovy, helping to boost
Ozempic maker Novo Nordisk reports 62% surge in profit
03:52am, Wednesday, 31'st Jan 2024
Novo Nordisk on Wednesday said its fourth-quarter profit surged by nearly two-thirds, driven by the popularity of its weight-loss drugs that have made it Europe's largest company.
Novo Nordisk Beats Profit Forecasts As Weight-Loss Sales Soar
03:39am, Wednesday, 31'st Jan 2024
Danish pharma giant Novo Nordisk on Wednesday reported better-than-expected earnings for 2023, propelled by a tsunami of demand for its blockbuster weight loss and diabetes drugs as new treatments eme
Novo Nordisk will more than double U.S. lower doses of Wegovy, CEO says
02:46am, Wednesday, 31'st Jan 2024
Novo Nordisk will more than double the amount of lower doses of its obesity drug Wegovy in the United States compared with recent months, CEO Lars Fruergaard Jorgensen said on Wednesday as the Danish
Novo Nordisk beats earnings expectations as Wegovy, Ozempic demand soars
02:20am, Wednesday, 31'st Jan 2024
Novo Nordisk, Europe's largest company by market capitalization, on Wednesday reported better-than-expected 2023 earnings.
Novo Nordisk Q4 profits beat expectations, expects double-digit growth in 2024
01:42am, Wednesday, 31'st Jan 2024
Novo Nordisk on Wednesday posted fourth-quarter operating profit above expectations as it forecast another year of double-digit record sales growth due to its wildly popular Wegovy weight-loss drug.
Big Earnings Afternoon: Microsoft, Alphabet, Starbucks & More
07:16pm, Tuesday, 30'th Jan 2024
Microsoft, Google-parent Alphabet, Mondelez and Skyworks all topped earnings expectations.
Wall Street Analysts See Novo Nordisk (NVO) as a Buy: Should You Invest?
10:31am, Tuesday, 30'th Jan 2024
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe
Is a Surprise Coming for Novo Nordisk (NVO) This Earnings Season?
07:01am, Tuesday, 30'th Jan 2024
Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
